

Annual report including audited financial statements as at 31st December 2023

Rhenman & Partners Fund

Investment Fund (F.C.P.), Luxembourg

R.C.S. Luxembourg K8



Management Company: FundRock Management Company S.A.
R.C.S. Luxembourg B 104 196

Notice

The sole legally binding basis for the purchase of units of the Fund described in this report is the latest valid sales prospectus with its terms of contract.

Rhenman & Partners Fund

Table of contents

| | |
|--|-----------|
| Organisation | 2 |
| Report from the Investment Manager | 4 |
| Audit report..... | 6 |
| Rhenman & Partners Fund - Rhenman Healthcare Equity L/S..... | 9 |
| Statement of net assets | 9 |
| Statement of operations..... | 10 |
| Statement of changes in net assets | 11 |
| Statistical information | 12 |
| Statement of investments and other net assets | 13 |
| Industrial and geographical classification of investments and short positions..... | 16 |
| Notes to the financial statements | 17 |
| Additional information (unaudited)..... | 24 |

Rhenman & Partners Fund

Organisation

**Management Company and
Alternative Investment Fund Manager
(AIFM)**

FundRock Management Company S.A.
33, rue de Gasperich
L-5826 Hesperange

**Board of Directors of
the Management Company
and the AIFM**

Chairman
Michel Marcel VAREIKA
Independent Non-Executive Director

Members
Frank DE BOER
Executive Director
(since 7th August 2023)

Romain DENIS
Executive Director
(until 17th July 2023)

Karl FÜHRER
Executive Director
(since 17th July 2023)

Thibault GREGOIRE
Executive Director
(until 15th September 2023)

Carmel MCGOVERN
Independent Non-Executive Director

Xavier PARAIN
Executive Director
(until 10th February 2023)

David RHYDDERCH
Non-Executive Director
(since 5th May 2023)

Depository and Paying Agent

Skandinaviska Enskilda Banken AB (publ) - Luxembourg Branch
4, rue Peternelchen
L-2370 Howald

**Administrative Agent including
Registrar and Transfer Agent**

UI efa S.A.
(formerly EUROPEAN FUND ADMINISTRATION S.A.)
2, rue d'Alsace
L-1122 Luxembourg

Portfolio Manager

Rhenman & Partners Asset Management AB
Strandvägen 5A
SE-114 51 Stockholm

Rhenman & Partners Fund

Organisation (continued)

| | |
|---|--|
| Auditor | PricewaterhouseCoopers, Société coopérative 2, rue Gerhard Mercator L-2182 Luxembourg |
| Global Distributor | FundRock Distribution S.A. 9A, rue Gabriel Lippmann L-5365 Munsbach (since 25th October 2023) |
| Placement and Distribution Agent | FundRock Management Company S.A. 33, rue de Gasperich L-5826 Hesperange (until 24th October 2023) |
| Prime Broker | Skandinaviska Enskilda Banken AB (publ) Kungsträdgårdsgatan 8 SE-106 40 Stockholm |
| Paying Agent in Sweden | Skandinaviska Enskilda Banken AB (publ) Kungsträdgårdsgatan 8 SE-106 40 Stockholm |

Rhenman & Partners Fund

Report from the Investment Manager

During the year ending 31st of December 2023, the EUR unit class (IC1, EUR) increased by 7.9 percent, the SEK unit class (RC1, SEK) increased by 6.1 percent and the USD unit class (IC1, USD) increased by 11.6 percent.

The fund aims to hold approximately one-third each of small, medium and large-cap healthcare companies over time. This strategy aims to achieve a balanced and diversified portfolio despite the focus on one specific industry. Diversification is also achieved through exposure to several different subsectors within the healthcare sphere: pharmaceuticals, biotechnology, medical technology and healthcare services.

As a whole, 2023 turned out to be a significantly better stock market year than most had anticipated at the beginning of the year. Even though, to a large degree, the overall performance rested on the so called Magnificent Seven (i.e. Apple, Microsoft, Alphabet, Amazon, Meta Platforms, Tesla and Nvidia) market breadth improved successively towards the end of the year. Inflation started to fall during second half of 2023 after reaching forty-year highs during 2022. At the end of 2023, the yield on the US 10-year government bonds stood at the same level as at the beginning of 2023 and some 120 basis points lower than at the peak in October. Investors started penciling in several interest rate cuts both in the US and in Europe.

The fund's best performing holding during the year was the US biotechnology company Immunogen. The company has a breakthrough treatment for ovarian cancer called Elahere. Elahere has showed an overall survival benefit of 33 percent compared to standard of care in heavily pre-treated patients with platinum refractory ovarian cancer. Uptake for the drug has steadily increased since launch and, in November 2023, pharmaceutical company AbbVie announced the acquisition of Immunogen for a 100 percent premium.

Pharmaceutical company Eli Lilly was the fund's next best contributor during the year. During 2023 the company had several data readouts for weight-loss drugs with stunning results. Obesity is linked to many chronic diseases and there has historically existed little to no effective drugs against obesity. Eli Lilly is one of the leaders within the GLP-1 obesity drug class.

The fund's worst performing holding was US biotech company Harmony Biosciences. The company's lead asset Wakix (pitolisant) is indicated for narcolepsy. A negative phase 3 trial studying pitolisant in an adjacent indication, idiopathic hypersomnia, has limited the full market potential of the drug.

The second worst performer was US biotech company Jazz Pharmaceuticals. The company is also active in narcolepsy with its products Xyrem and Xyway. The aforementioned competing orexin drug class has had similar negative impact for Jazz. Furthermore, an ongoing patent litigation with the FDA regarding Xyrem and Xyway has created uncertainty around uptake and presented a challenge for the company.

There are prospects for 2024 to be a strong year for the healthcare sector despite the high level of geopolitical uncertainty and numerous elections around the world. If 2024 turns out to be a good stock market year for healthcare, it may well be that we may see the strongest developments at the end of the year.

Optimism is growing that healthcare and pharmaceuticals will not be the subject of new major reforms in the US in the coming years. Rate cuts should benefit the sector on a broad basis; large companies should then enjoy higher valuations in the form of P/E expansion and small companies could once again look forward to better conditions for capital raising through new issues and IPOs. Lower interest rates should provide better conditions for acquisitions, which benefit both the purchasing companies and the potential acquisition targets.

Rhenman & Partners Fund

Report from the Investment Manager (continued)

We do, however, continue to aim for a balanced level of risk taking on or around current levels. Even though the smaller companies seem set to enjoy improved conditions, we believe that it is still reasonable to have diversified portfolio with the emphasis on large and medium-sized companies. We live in a troubled world where inflation could suddenly take off in a series of geopolitical entanglements. Fears might then reappear that future interest rate cuts in the US could be delayed.

Luxembourg, 3rd May 2024

The Investment Manager

Note: The information in this report represents historical data and is not an indication of future results.



Audit report

To the Unitholders of
Rhenman & Partners Fund

Our opinion

In our opinion, the accompanying financial statements give a true and fair view of the financial position of Rhenman & Partners Fund (the “Fund”) as at 31 December 2023, and of the results of its operations and changes in its net assets for the year then ended in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the financial statements.

What we have audited

The Fund’s financial statements comprise:

- the statement of net assets as at 31 December 2023;
- the statement of operations for the year then ended;
- the statement of changes in net assets for the year then ended; and
- the notes to the financial statements, which include a summary of significant accounting policies.

Basis for opinion

We conducted our audit in accordance with the Law of 23 July 2016 on the audit profession (Law of 23 July 2016) and with International Standards on Auditing (ISAs) as adopted for Luxembourg by the “Commission de Surveillance du Secteur Financier” (CSSF). Our responsibilities under the Law of 23 July 2016 and ISAs as adopted for Luxembourg by the CSSF are further described in the “Responsibilities of the “Réviseur d’entreprises agréé” for the audit of the financial statements” section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

We are independent of the Fund in accordance with the International Code of Ethics for Professional Accountants, including International Independence Standards, issued by the International Ethics Standards Board for Accountants (IESBA Code) as adopted for Luxembourg by the CSSF together with the ethical requirements that are relevant to our audit of the financial statements. We have fulfilled our other ethical responsibilities under those ethical requirements.

Other information

The Board of Directors of the Management Company is responsible for the other information. The other information comprises the information stated in the annual report but does not include the financial statements and our audit report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors of the Management Company for the financial statements

The Board of Directors of the Management Company is responsible for the preparation and fair presentation of the financial statements in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the financial statements, and for such internal control as the Board of Directors of the Management Company determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors of the Management Company is responsible for assessing the Fund's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors of the Management Company either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Responsibilities of the “Réviseur d’entreprises agréé” for the audit of the financial statements

The objectives of our audit are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an audit report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control;
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors of the Management Company;



- conclude on the appropriateness of the Board of Directors of the Management Company's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our audit report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However, future events or conditions may cause the Fund to cease to continue as a going concern;
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

PricewaterhouseCoopers, Société coopérative
Represented by

Luxembourg, 25 June 2024

Philippe Sergiel

Rhenman & Partners Fund - Rhenman Healthcare Equity L/S

Statement of net assets (in EUR)

as at 31st December 2023

Assets

Investments

| | |
|--------------------------------------|-------------------------|
| Securities portfolio at market value | 1,155,372,098.89 |
| | <u>1,155,372,098.89</u> |

Cash and cash equivalents

| | |
|---------------|---------------------|
| Cash at banks | 4,175,332.27 |
| | <u>4,175,332.27</u> |

Receivables

| | |
|--------------------------------------|---------------------|
| Receivable on sales of securities | 2,038,394.04 |
| Receivable on issues of units | 677,885.42 |
| Income receivable on portfolio | 493,665.50 |
| Interest receivable on bank accounts | 7,505.45 |
| | <u>3,217,450.41</u> |

Total assets

1,162,764,881.57

Liabilities

Payables

| | |
|---|-----------------------|
| Short sales of securities at market value | 111,396,706.05 |
| Payable on purchases of securities | 19,204,101.79 |
| Payable on redemptions of units | 22,302,262.62 |
| Income payable on short position on portfolio | 28,237.75 |
| Bank interest payable | 1,218,615.39 |
| Expenses payable | 3,239,192.27 |
| | <u>157,389,115.87</u> |

Borrowings

| | |
|------------------------------|-----------------------|
| Bank overdrafts | 30.51 |
| Collateralized debt at banks | 190,709,377.92 |
| | <u>190,709,408.43</u> |

Total liabilities

348,098,524.30

Total net assets at the end of the year

814,666,357.27

Breakdown of net assets per unit class

| Unit class | Number of units | Currency of unit class | NAV per unit in currency of unit class | Net assets per unit class (in EUR) |
|------------|-----------------|------------------------|--|------------------------------------|
| IC1 (EUR) | 69,951.914 | EUR | 871.16 | 60,938,976.97 |
| IC1 (USD) | 101,858.482 | USD | 215.29 | 19,853,763.74 |
| IC2 (SEK) | 223,983.090 | SEK | 704.13 | 14,172,139.39 |
| IC2 (USD) | 57,116.235 | USD | 297.63 | 15,390,337.06 |
| IC3 (EUR) | 46,557.223 | EUR | 1,103.39 | 51,370,729.37 |
| IC4 (EUR) | 242,066.328 | EUR | 710.64 | 172,022,647.04 |
| ID1 (SEK) | 1,450,467.425 | SEK | 421.76 | 54,971,815.32 |
| RC1 (EUR) | 9,953.922 | EUR | 743.20 | 7,397,753.62 |
| RC1 (SEK) | 2,352,897.900 | SEK | 817.05 | 172,750,780.01 |
| RC2 (SEK) | 2,676,380.026 | SEK | 870.49 | 209,355,068.31 |
| RC2 (USD) | 292,278.354 | USD | 137.72 | 36,442,346.44 |
| | | | | <u><u>814,666,357.27</u></u> |

The accompanying notes are an integral part of these financial statements.

Rhenman & Partners Fund - Rhenman Healthcare Equity L/S

Statement of operations (in EUR)

from 1st January 2023 to 31st December 2023

Income

Investment income

| | |
|---------------------------|---------------------|
| Dividends, net | 8,309,349.41 |
| Interest on bank accounts | 312,846.12 |
| | <u>8,622,195.53</u> |

Realised gain on investments

| | |
|---------------------------|-----------------------|
| - on securities portfolio | 184,672,062.85 |
| - on foreign exchange | 2,608,769.39 |
| | <u>187,280,832.24</u> |

Unrealised gains on investments

| | |
|---------------------------|-----------------------|
| - on securities portfolio | 256,866,664.24 |
| | <u>256,866,664.24</u> |

Total income

452,769,692.01

Expenses

Investment advisory or management fees

| | |
|------------------|----------------------|
| Management fees | 13,690,629.27 |
| Performance fees | 7,322,441.01 |
| | <u>21,013,070.28</u> |

Other expenses

| | |
|---|----------------------|
| Depository fees | 164,627.86 |
| Banking charges and other fees | 2,170,054.64 |
| Transaction fees | 655,631.72 |
| Central administration costs | 575,526.34 |
| Professional fees | 53,525.12 |
| Other administration costs | 80,336.25 |
| Subscription duty ("taxe d'abonnement") | 253,577.75 |
| Bank interest paid | 10,438.15 |
| Dividends paid on short sales of securities | 933,916.18 |
| Interest paid on collateralized debt at banks | 10,327,912.92 |
| | <u>15,225,546.93</u> |

Realised loss on investments

| | |
|---------------------------|-----------------------|
| - on securities portfolio | 230,420,378.45 |
| | <u>230,420,378.45</u> |

Unrealised loss on investments

| | |
|---------------------------|-----------------------|
| - on securities portfolio | 131,045,100.16 |
| | <u>131,045,100.16</u> |

Total expenses

397,704,095.82

Net income

55,065,596.19

The accompanying notes are an integral part of these financial statements.

Rhenman & Partners Fund - Rhenman Healthcare Equity L/S

Statement of changes in net assets (in EUR)

from 1st January 2023 to 31st December 2023

| | |
|--|-----------------------|
| Net income | 55,065,596.19 |
| Dividends paid | -2,221,900.29 |
| Subscriptions | 36,457,005.64 |
| Redemptions | -136,531,928.53 |
| Total changes in net assets | -47,231,226.99 |
| Total net assets at the beginning of the year | 861,897,584.26 |
| Total net assets at the end of the year | 814,666,357.27 |

The accompanying notes are an integral part of these financial statements.

Rhenman & Partners Fund - Rhenman Healthcare Equity L/S

Statistical information (in EUR)

as at 31st December 2023

| Total net assets | Currency | 31.12.2021 | 31.12.2022 | 31.12.2023 |
|------------------|----------|------------------|----------------|----------------|
| | EUR | 1,003,381,589.23 | 861,897,584.26 | 814,666,357.27 |

| Net asset value per unit class | Currency | 31.12.2021 | 31.12.2022 | 31.12.2023 |
|--------------------------------|----------|------------|------------|------------|
| IC1 (EUR) | EUR | 880.28 | 807.60 | 871.16 |
| IC1 (USD) | USD | 223.90 | 192.89 | 215.29 |
| IC2 (SEK) | SEK | 660.56 | 658.76 | 704.13 |
| IC2 (USD) | USD | 306.45 | 265.32 | 297.63 |
| IC3 (EUR) | EUR | 1,098.35 | 1,015.25 | 1,103.39 |
| IC4 (EUR) | EUR | 713.00 | 659.06 | 710.64 |
| ID1 (SEK) | SEK | 434.40 | 412.06 | 421.76 |
| RC1 (EUR) | EUR | 759.14 | 692.71 | 743.20 |
| RC1 (SEK) | SEK | 780.47 | 770.01 | 817.05 |
| RC2 (SEK) | SEK | 824.34 | 817.47 | 870.49 |
| RC2 (USD) | USD | 141.91 | 122.82 | 137.72 |

| Number of units | outstanding at the beginning of the year | issued | redeemed | outstanding at the end of the year |
|-----------------|--|-------------|--------------|------------------------------------|
| IC1 (EUR) | 93,107.455 | 3,881.318 | -27,036.859 | 69,951.914 |
| IC1 (USD) | 112,935.123 | 13,323.229 | -24,399.870 | 101,858.482 |
| IC2 (SEK) | 150,000.001 | 108,234.737 | -34,251.648 | 223,983.090 |
| IC2 (USD) | 57,180.741 | - | -64.506 | 57,116.235 |
| IC3 (EUR) | 46,998.846 | - | -441.623 | 46,557.223 |
| IC4 (EUR) | 272,669.350 | - | -30,603.022 | 242,066.328 |
| ID1 (SEK) | 1,515,973.378 | 12,113.591 | -77,619.544 | 1,450,467.425 |
| RC1 (EUR) | 12,336.366 | 554.557 | -2,937.001 | 9,953.922 |
| RC1 (SEK) | 2,810,990.679 | 104,417.522 | -562,510.301 | 2,352,897.900 |
| RC2 (SEK) | 3,163,211.491 | 95,203.103 | -582,034.568 | 2,676,380.026 |
| RC2 (USD) | 209,125.186 | 83,153.168 | - | 292,278.354 |

| Dividends paid | Currency | Dividend per unit class | Ex-dividend date |
|----------------|----------|-------------------------|------------------|
| ID1 (SEK) | SEK | 15.58 | 28.02.2023 |
| ID1 (SEK) | SEK | 0.90 | 30.06.2023 |

Rhenman & Partners Fund - Rhenman Healthcare Equity L/S

Statement of investments and other net assets (in EUR)

as at 31st December 2023

| Currency | Number / nominal value | Description | Cost | Market value | % of total net assets * |
|---|------------------------|-----------------------------------|---------------|---------------|-------------------------|
| Securities: investments and short positions | | | | | |
| Transferable securities admitted to an official stock exchange listing | | | | | |
| Shares | | | | | |
| AUD | 368,701 | Anteris Technologies Ltd | 5,085,436.21 | 4,361,471.96 | 0.54 |
| AUD | 30,000 | CSL Ltd | 1,358,136.00 | 5,312,062.70 | 0.65 |
| | | | 6,443,572.21 | 9,673,534.66 | 1.19 |
| CHF | 20,000 | Lonza Group AG Reg | 8,959,524.00 | 7,609,360.27 | 0.93 |
| CHF | 37,500 | Roche Holding AG B de jousis Pref | 9,277,074.44 | 9,862,640.94 | 1.21 |
| CHF | 82,500 | Straumann Holding AG | 10,587,817.67 | 12,033,632.08 | 1.48 |
| | | | 28,824,416.11 | 29,505,633.29 | 3.62 |
| DKK | 581,737 | Alk-Abello A/S | 6,506,566.53 | 7,897,602.31 | 0.97 |
| DKK | 56,000 | Genmab A/S | 13,160,444.09 | 16,189,124.50 | 1.98 |
| DKK | 334,050 | Novo Nordisk AS B | 17,041,351.63 | 31,283,632.50 | 3.84 |
| DKK | 70,000 | Zealand Pharma A/S | 2,184,712.93 | 3,504,513.49 | 0.43 |
| | | | 38,893,075.18 | 58,874,872.80 | 7.22 |
| EUR | 34,000 | Argenx SE | 9,674,536.99 | 11,679,000.00 | 1.43 |
| EUR | 275,000 | Sanofi SA | 24,207,188.68 | 24,684,000.00 | 3.03 |
| EUR | 110,000 | UCB | 8,421,114.59 | 8,679,000.00 | 1.07 |
| | | | 42,302,840.26 | 45,042,000.00 | 5.53 |
| GBP | 2,200,000 | ConvaTec Group Plc Reg | 5,542,260.94 | 6,201,448.55 | 0.76 |
| JPY | 299,700 | Chugai Pharmaceutical Co Ltd | 4,980,219.83 | 10,276,555.25 | 1.26 |
| JPY | 161,000 | Santen Pharmaceutical Co Ltd | 1,691,894.12 | 1,451,974.99 | 0.18 |
| JPY | 695,000 | Takeda Pharmaceutical Co Ltd | 20,502,800.37 | 18,085,290.28 | 2.22 |
| JPY | 211,700 | Terumo Corp | 4,338,543.96 | 6,280,695.44 | 0.77 |
| | | | 31,513,458.28 | 36,094,515.96 | 4.43 |
| NOK | 895,205 | CSAM Health Group AS | 5,755,025.29 | 2,952,940.12 | 0.36 |
| SEK | 322,000 | AstraZeneca Plc | 34,130,156.70 | 39,163,698.33 | 4.81 |
| SEK | 244,851 | BioArctic AB Reg B | 6,109,884.83 | 5,892,261.59 | 0.72 |
| SEK | 450,000 | BioInvent Intl AB | 2,108,094.48 | 766,691.08 | 0.09 |
| SEK | 92,316 | Camurus AB | 3,876,110.57 | 4,463,019.86 | 0.55 |
| SEK | 12,666,824 | Episurf Medical AB B | 4,924,748.99 | 1,126,866.57 | 0.14 |
| SEK | 205,000 | Vitrolife AB Reg | 4,432,126.12 | 3,586,653.13 | 0.44 |
| | | | 55,581,121.69 | 54,999,190.56 | 6.75 |
| USD | 205,000 | Abbott Laboratories | 19,479,041.34 | 20,428,545.56 | 2.51 |
| USD | 167,000 | AbbVie Inc | 17,641,273.69 | 23,430,347.20 | 2.88 |
| USD | 18,624 | Acadia Healthcare Co Inc | 1,327,893.79 | 1,311,124.20 | 0.16 |
| USD | 27,000 | Align Technology Inc | 5,157,616.32 | 6,697,750.22 | 0.82 |
| USD | 950,000 | Alignment Healthcare Inc | 10,061,768.98 | 7,405,278.17 | 0.91 |
| USD | 340,000 | Alkermes Plc | 8,735,424.94 | 8,538,861.98 | 1.04 |
| USD | 37,500 | Alnylam Pharmaceuticals Inc | 4,793,529.31 | 6,498,460.91 | 0.80 |
| USD | 370,000 | Ambrx Biopharma Inc | 4,493,551.25 | 4,770,087.37 | 0.59 |
| USD | 4,500 | Amgen Inc | 1,145,913.85 | 1,173,409.99 | 0.14 |
| USD | 100,400 | Apellis Pharmaceuticals Inc Reg | 4,125,641.16 | 5,441,079.17 | 0.67 |
| USD | 134,270 | Arvinas Inc Reg | 5,869,599.41 | 5,003,443.21 | 0.61 |
| USD | 292,000 | Avantor Inc Reg | 6,008,902.63 | 6,035,362.82 | 0.74 |
| USD | 220,000 | Axonics Inc Reg | 8,981,658.96 | 12,394,730.89 | 1.52 |
| USD | 79,100 | Axsome Therapeutics Inc | 4,833,808.74 | 5,699,668.64 | 0.70 |
| USD | 16,000 | Bio-Techne Corp | 1,043,826.96 | 1,117,704.04 | 0.14 |
| USD | 58,672 | Biogen Inc | 15,799,981.23 | 13,745,465.07 | 1.68 |
| USD | 282,500 | BioMarin Pharmaceutical Inc | 22,561,786.51 | 24,660,404.69 | 3.03 |
| USD | 750,000 | Boston Scientific Corp | 30,916,108.74 | 39,253,542.17 | 4.82 |
| USD | 135,000 | BridgeBio Pharma Inc Reg | 2,159,275.16 | 4,934,090.81 | 0.61 |
| USD | 16,000 | Bruker Corp | 1,040,864.10 | 1,064,397.27 | 0.13 |
| USD | 96,000 | Cencora Inc | 12,368,384.80 | 17,850,237.65 | 2.19 |
| USD | 135,000 | Centene Corp | 9,109,788.04 | 9,070,073.79 | 1.11 |
| USD | 38,000 | Charles River Labo Intl Inc Reg | 7,320,845.27 | 8,132,904.80 | 1.00 |
| USD | 47,000 | Cigna Group Reg | 12,740,193.58 | 12,741,976.37 | 1.56 |
| USD | 58,500 | Cooper Companies Inc (The) | 17,532,883.55 | 20,043,750.85 | 2.46 |

* Minor differences may arise due to rounding in the calculation of percentages.

The accompanying notes are an integral part of these financial statements.

Rhenman & Partners Fund - Rhenman Healthcare Equity L/S

Statement of investments and other net assets (in EUR) (continued)

as at 31st December 2023

| Currency | Number / nominal value | Description | Cost | Market value | % of total net assets * |
|---------------------|------------------------|----------------------------------|------------------|------------------|-------------------------|
| USD | 137,500 | CVS Health Corp | 9,128,314.05 | 9,829,342.27 | 1.21 |
| USD | 149,912 | Cytokinetics Inc | 6,356,578.76 | 11,331,449.80 | 1.39 |
| USD | 78,000 | Danaher Corp | 16,127,438.85 | 16,336,535.24 | 2.01 |
| USD | 110,000 | Dexcom Inc | 9,746,368.18 | 12,357,883.30 | 1.52 |
| USD | 800,000 | Dynavax Technologies Corp | 6,475,636.87 | 10,125,390.43 | 1.24 |
| USD | 13,000 | Elevance Health Inc | 4,590,390.10 | 5,550,024.90 | 0.68 |
| USD | 78,005 | Eli Lilly & Co | 22,723,085.99 | 41,166,696.48 | 5.05 |
| USD | 356,500 | Essa Pharma Inc | 3,673,953.37 | 2,130,188.76 | 0.26 |
| USD | 230,000 | Evolent Health Inc | 6,901,572.89 | 6,877,823.55 | 0.84 |
| USD | 165,000 | Exact Sciences Corp Reg | 11,469,341.13 | 11,051,287.85 | 1.36 |
| USD | 259,000 | Gilead Sciences Inc | 18,113,668.06 | 18,995,600.02 | 2.33 |
| USD | 120,000 | Glaukos Corp | 6,655,567.81 | 8,635,915.08 | 1.06 |
| USD | 109,000 | HCA Healthcare Inc | 24,416,311.90 | 26,711,439.05 | 3.27 |
| USD | 300,000 | Health Catalyst Inc Reg | 8,171,259.04 | 2,515,051.38 | 0.31 |
| USD | 39,083 | Humana Inc | 16,892,345.12 | 16,198,984.41 | 1.98 |
| USD | 200,000 | IGM Biosciences Inc | 3,002,882.53 | 1,504,685.17 | 0.18 |
| USD | 84,278 | Immunocore Hgs PLC ADR DR | 2,935,398.52 | 5,212,867.65 | 0.64 |
| USD | 146,061 | Immunovant Inc | 2,875,345.28 | 5,571,092.24 | 0.68 |
| USD | 178,284 | INmune Bio Inc | 1,209,749.72 | 1,817,462.17 | 0.22 |
| USD | 18,000 | Inspire Medical Systems Inc | 3,194,009.56 | 3,315,141.91 | 0.41 |
| USD | 19,000 | Insulet Corp | 2,667,162.12 | 3,732,397.81 | 0.46 |
| USD | 50,000 | Intellia Therapeutics Inc | 3,778,908.09 | 1,380,200.08 | 0.17 |
| USD | 90,000 | Intra-Cellular Therapies Inc | 1,644,285.65 | 5,835,679.69 | 0.72 |
| USD | 63,500 | Intuitive Surgical Inc | 16,751,367.20 | 19,394,649.40 | 2.38 |
| USD | 1,116,818 | Iovance Biotherapeutics Inc Reg | 11,223,258.20 | 8,220,298.17 | 1.01 |
| USD | 45,000 | IQVIA Holdings Inc Reg | 8,629,993.31 | 9,426,553.80 | 1.16 |
| USD | 123,634 | Jazz Pharmaceuticals Plc | 15,710,991.82 | 13,767,581.37 | 1.69 |
| USD | 15,000 | Laboratory Corp of America Hgs | 3,082,807.93 | 3,086,641.62 | 0.38 |
| USD | 40,000 | Lantheus Holdings Inc | 3,030,480.62 | 2,245,258.25 | 0.28 |
| USD | 22,500 | Madrigal Pharmaceuticals Inc ADR | 4,083,991.83 | 4,713,276.90 | 0.58 |
| USD | 46,000 | McKesson Corp | 12,559,291.52 | 19,281,227.65 | 2.37 |
| USD | 591,000 | Medtronic Plc Reg | 45,991,216.66 | 44,078,203.79 | 5.41 |
| USD | 32,091 | MeiraGTx Holdings Reg Plc | 442,295.30 | 203,955.29 | 0.02 |
| USD | 147,500 | Merck & Co Inc | 11,469,651.50 | 14,558,372.19 | 1.79 |
| USD | 245,000 | Natera Inc Reg | 11,161,178.80 | 13,894,165.04 | 1.71 |
| USD | 62,000 | Neurocrine Biosciences Inc | 5,706,233.80 | 7,395,880.67 | 0.91 |
| USD | 160,000 | NovoCure Ltd Reg | 1,955,843.20 | 2,162,690.69 | 0.27 |
| USD | 112,929 | Nuvalent Inc | 3,972,548.43 | 7,523,828.81 | 0.92 |
| USD | 1,192,054 | Oscar Health Inc | 6,865,687.85 | 9,874,875.83 | 1.21 |
| USD | 2,500 | Penumbra Inc Reg | 542,966.42 | 569,326.88 | 0.07 |
| USD | 580,000 | Pfizer Inc | 15,471,230.79 | 15,117,649.72 | 1.86 |
| USD | 112,741 | Pliant Therapeutics Inc | 1,655,247.22 | 1,848,480.84 | 0.23 |
| USD | 460,000 | Privia Health Group Inc | 11,097,881.76 | 9,591,055.18 | 1.18 |
| USD | 310,000 | Procept Biorobotics Corp | 9,305,278.69 | 11,762,346.66 | 1.44 |
| USD | 25,000 | Pulmonx Corp | 291,497.53 | 288,579.06 | 0.04 |
| USD | 39,000 | Regeneron Pharmaceuticals Inc | 25,091,801.74 | 31,011,099.55 | 3.81 |
| USD | 390,000 | Relay Therapeutics Inc | 4,786,781.90 | 3,887,465.48 | 0.48 |
| USD | 10,000 | Repligen Corp Reg | 1,522,179.71 | 1,627,812.23 | 0.20 |
| USD | 475,872 | Revance Therapeutics Inc | 7,724,153.81 | 3,786,985.54 | 0.46 |
| USD | 429,697 | Royalty Pharma Plc A Reg | 13,218,275.63 | 10,927,697.91 | 1.34 |
| USD | 140,000 | ShockWave Medical Inc Reg | 25,400,978.48 | 24,153,184.55 | 2.97 |
| USD | 5,000 | Stryker Corp | 1,366,826.31 | 1,355,574.67 | 0.17 |
| USD | 351,630 | Tenet Healthcare Corp Reg | 19,604,525.78 | 24,057,470.55 | 2.95 |
| USD | 160,000 | TG Therapeutics Inc | 3,409,812.35 | 2,474,129.74 | 0.30 |
| USD | 33,500 | Thermo Fisher Scientific Inc | 14,771,140.76 | 16,098,379.43 | 1.98 |
| USD | 54,000 | United Health Group Inc | 23,698,835.52 | 25,738,427.41 | 3.16 |
| USD | 95,000 | Vertex Pharmaceuticals Inc | 21,094,781.87 | 34,995,744.87 | 4.30 |
| USD | 180,000 | Viking Therapeutics Inc | 2,370,510.02 | 3,032,728.26 | 0.37 |
| USD | 9,000 | West Pharmaceutical Serv Inc Reg | 2,304,530.62 | 2,869,114.12 | 0.35 |
| USD | 225,000 | Xencor Inc | 5,675,257.65 | 4,324,611.84 | 0.53 |
| USD | 55,000 | Zimmer Biomet Hgs Inc | 6,722,019.16 | 6,059,933.91 | 0.74 |
| | | | 807,762,487.59 | 911,031,094.95 | 111.83 |
| Total shares | | | 1,022,618,257.55 | 1,154,375,230.89 | 141.69 |

* Minor differences may arise due to rounding in the calculation of percentages.

The accompanying notes are an integral part of these financial statements.

Rhenman & Partners Fund - Rhenman Healthcare Equity L/S

Statement of investments and other net assets (in EUR) (continued)

as at 31st December 2023

| Currency | Number / nominal value | Description | Cost | Market value | % of total net assets * |
|---|------------------------|---------------------------------------|----------------|-----------------------|-------------------------|
| <u>Short positions in transferable securities admitted to an official stock exchange listing</u> | | | | | |
| Shares | | | | | |
| CHF | -7,500 | Novartis AG Reg | -687,769.26 | -684,697.21 | -0.08 |
| DKK | -20,000 | Demant AS Reg | -787,869.74 | -794,163.22 | -0.10 |
| EUR | -30,000 | Grifols SA A | -415,926.00 | -463,650.00 | -0.06 |
| JPY | -15,000 | Shionogi & Co Ltd | -680,669.86 | -654,529.69 | -0.08 |
| USD | -100,000 | Adapthealth Corp | -748,540.99 | -659,997.28 | -0.08 |
| USD | -40,000 | Agilent Technologies Inc Reg | -3,904,448.85 | -5,034,810.56 | -0.62 |
| USD | -100,000 | Agilon Health Inc | -1,060,922.07 | -1,136,209.32 | -0.14 |
| USD | -23,000 | AMN Healthcare Serv Inc | -1,442,056.32 | -1,559,223.21 | -0.19 |
| USD | -75,000 | Baxter Intl Inc | -3,008,859.20 | -2,625,050.93 | -0.32 |
| USD | -45,000 | Bristol Myers Squibb Co | -2,730,423.42 | -2,090,398.80 | -0.26 |
| USD | -14,000 | Catalent Inc | -493,493.84 | -569,480.78 | -0.07 |
| USD | -7,500 | Edwards Lifesciences Corp | -504,736.46 | -517,744.78 | -0.06 |
| USD | -30,000 | Envista Holdings Corporation Reg | -626,376.10 | -653,478.79 | -0.08 |
| USD | -34,000 | Fortrea Holdings Inc | -991,288.19 | -1,074,283.64 | -0.13 |
| USD | -10,000 | IDEXX Laboratories Inc | -3,833,498.89 | -5,025,123.35 | -0.62 |
| USD | -1,500 | Inari Medical inc | -80,358.92 | -88,162.60 | -0.01 |
| USD | -10,000 | Johnson & Johnson | -1,422,574.34 | -1,419,039.43 | -0.17 |
| USD | -7,500 | Moderna Inc Reg | -515,263.55 | -675,275.00 | -0.08 |
| USD | -118,000 | Pediatrix Medical Group Inc | -1,024,047.62 | -993,526.78 | -0.12 |
| USD | -25,000 | Premier Inc A Reg | -496,593.33 | -506,088.45 | -0.06 |
| USD | -37,000 | Quest Diagnostics Inc | -4,518,474.71 | -4,618,677.29 | -0.57 |
| USD | -20,000 | Revvity Inc | -1,554,802.74 | -1,979,267.58 | -0.24 |
| USD | -11,000 | Select Medical Holdings Corp Reg | -244,722.74 | -234,031.96 | -0.03 |
| USD | -5,000 | Steris Plc Reg | -942,836.77 | -995,201.67 | -0.12 |
| USD | -47,000 | Walgreens Boots Alliance Inc | -1,008,712.74 | -1,111,013.53 | -0.14 |
| USD | -22,000 | Waters Corp | -5,418,407.51 | -6,557,475.90 | -0.80 |
| | | | -36,571,439.30 | -40,123,561.63 | -4.91 |
| Total shares | | | -39,143,674.16 | -42,720,601.75 | -5.23 |
| <u>Transferable securities dealt in on another regulated market</u> | | | | | |
| Shares | | | | | |
| SEK | 1,562,463 | Bio-Works Technologies AB Reg | 1,328,276.96 | 996,868.00 | 0.12 |
| Total shares | | | 1,328,276.96 | 996,868.00 | 0.12 |
| <u>Short positions in open-ended investment funds</u> | | | | | |
| Tracker funds (UCI) | | | | | |
| USD | -310,000 | iShares Trust Nasdaq Biotech ETF Dist | -32,149,338.10 | -38,127,291.66 | -4.68 |
| USD | -377,900 | SPDR Ser Trust S&P Biotech ETF Dist | -31,448,800.06 | -30,548,812.64 | -3.75 |
| Total tracker funds (UCI) | | | -63,598,138.16 | -68,676,104.30 | -8.43 |
| Total securities: investments and short positions | | | 921,204,722.19 | 1,043,975,392.84 | 128.15 |
| Cash at banks | | | | 4,175,332.27 | 0.51 |
| Bank overdrafts and collateralized debt at banks | | | | -190,709,408.43 | -23.41 |
| Other net assets/(liabilities) | | | | -42,774,959.41 | -5.25 |
| Total | | | | 814,666,357.27 | 100.00 |

* Minor differences may arise due to rounding in the calculation of percentages.

The accompanying notes are an integral part of these financial statements.

Rhenman & Partners Fund - Rhenman Healthcare Equity L/S

Industrial and geographical classification of investments and short positions as at 31st December 2023

Industrial classification

(in percentage of net assets)

| | |
|-----------------------------|-----------------|
| Healthcare | 133.12 % |
| Financials | 2.55 % |
| Industrials | 0.74 % |
| Technologies | 0.31 % |
| Non-cyclical consumer goods | -0.14 % |
| Investment funds | -8.43 % |
| Total | <u>128.15 %</u> |

Geographical classification

(by domicile of the issuer)
(in percentage of net assets)

| | |
|--------------------------|-----------------|
| United States of America | 87.94 % |
| Ireland | 8.02 % |
| United Kingdom | 7.55 % |
| Denmark | 7.12 % |
| Japan | 4.35 % |
| Switzerland | 3.54 % |
| France | 3.03 % |
| Sweden | 2.06 % |
| The Netherlands | 1.43 % |
| Australia | 1.19 % |
| Belgium | 1.07 % |
| Norway | 0.36 % |
| Jersey | 0.27 % |
| Canada | 0.26 % |
| Cayman Islands | 0.02 % |
| Spain | -0.06 % |
| Total | <u>128.15 %</u> |

Rhenman & Partners Fund

Notes to the financial statements

as at 31st December 2023

Note 1 - General information

Rhenman & Partners Fund (the "Fund") is an open-ended mutual investment fund set up under the laws of the Grand Duchy of Luxembourg as a "*Fonds Commun de Placement*" ("FCP") registered pursuant to Part II of the amended Law of 17th December 2010 (the "2010 Law") relating to Undertakings for Collective Investment and qualifies as an Alternative Investment Fund ("AIF") in accordance with the law of 12th July 2013 (the "2013 Law") on Alternative Investment Fund Managers.

The financial year of the Fund ends on 31st December.

The financial statements of the Fund are expressed in EUR and correspond to the financial statements of the sole Sub-Fund open.

The Net Asset Value per unit of the Sub-Fund is calculated monthly as of the last Business Day of each month in Luxembourg ("Valuation Day"), under the overall responsibility of the AIFM.

The Net Asset Value per unit of each class, subscription and redemption prices in the Sub-Fund are available at the registered office of the AIFM.

Financial reports of the Fund are published annually and semi-annually. These reports, as well as the sales prospectus and other information concerning the Fund are available at the registered office of the Management Company, the Global Distributor or its Agents (if any) and the Depositary.

Note 2 - Significant accounting policies

a) Presentation of the financial statements

The financial statements of the Fund are prepared in accordance with the Luxembourg legal and regulatory requirements concerning Undertakings for Collective Investment and with generally accepted accounting principles in Luxembourg. The financial statements follow the presentation as defined by Article 104 of the Commission Delegated Regulation (EU) N° 231/2013.

The financial statements of the Fund have been prepared on a going concern basis.

b) Valuation

- 1) The value of any cash on hand or on deposit, bills and demand notes and accounts receivable, prepaid expenses, cash dividends and interest declared or accrued as aforesaid and not yet received is deemed to be the full amount thereof, unless in any case the same is unlikely to be paid or received in full, in which case the value thereof is arrived at after making such discount as may be considered appropriate in such case to reflect the true value thereof.
- 2) The value of assets, which are listed or dealt in on any stock exchange, is based on the last available price of the last business day on the stock exchange, which is normally the principal market for such assets.
- 3) The value of assets dealt in on any other regulated market which is recognised, operating regularly and open to the public (a "Regulated Market") is based on the closing price of the last business day.
- 4) In the event that any assets are not listed or dealt in on any stock exchange or on any other Regulated Market, or if, with respect to assets listed or dealt in on any stock exchange, or other Regulated Market as aforesaid, the price as determined pursuant to sub-paragraph (2) or (3) is not representative of the fair market value of the relevant assets, the value of such assets will be based on the reasonably foreseeable sales price determined prudently and in good faith by the Board of Directors of the AIFM.
- 5) The liquidating value of options contracts not traded on exchanges or on other Regulated Markets is their net liquidating value determined, pursuant to the policies established by the AIFM, on a basis consistently

Rhenman & Partners Fund

Notes to the financial statements (continued)

as at 31st December 2023

applied for each different variety of contracts. The liquidating value of futures, forward or options contracts traded on exchanges or on other Regulated Markets are based upon the closing prices of these contracts on the last business day on exchanges and Regulated Markets on which the particular futures, forward or options contracts are traded by the Fund; provided that if a futures, forward or options contract could not be liquidated on the day with respect to which net assets are being determined, the basis for determining the liquidating value of such contract shall be such value as the Board of Directors of the AIFM may deem fair and reasonable.

- 6) Units or shares of open-ended underlying funds are valued at their last determined and available Net Asset Value or, if such price is not representative of the fair market value of such assets, then the price shall be determined by the Board of Directors of the AIFM on a fair and equitable basis and in good faith. Exchange Traded Funds ("ETFs") are priced as assets listed or dealt in on any stock exchange.
- 7) All other securities and other assets are valued at fair market value as determined in good faith pursuant to the procedures established by the AIFM.

c) Acquisition cost of securities

The acquisition cost of a security denominated in a currency other than that of the Sub-Fund is converted to the Sub-Fund's currency at the exchange rate prevailing on the date of purchase.

d) Net realised gain/(loss) on securities portfolio

The net realised gain/(loss) on securities portfolio is determined on the basis of the average cost of securities sold.

e) Investment income

Dividend income is recognised on an ex-dividend basis and is recorded net of withholding tax.

Interest income is accrued on a *pro rata temporis* basis, net of any withholding tax.

f) Formation expenses

Expenses incurred in connection with the establishment of the Fund and the creation of the Sub-Fund are amortised over a period of five years. Formation expenses were fully amortised on a straight line basis over a period of five years.

g) Exchange translation

Bank balances, other assets and liabilities and the value of securities held that are denominated in other currencies than the Sub-Fund's currency are converted at the prevailing exchange rate of the closing day. Income and expenses incurred in currencies other than the Sub-Fund's currency are converted at the prevailing exchange rate of the day of each transaction.

At the date of the financial statements, the prevailing exchange rates on the closing day were as follows:

| | | | | | |
|---|-----|---|-------------|-----|-------------------|
| 1 | EUR | = | 1.6188627 | AUD | Australian Dollar |
| | | | 0.9296445 | CHF | Swiss Franc |
| | | | 7.4543871 | DKK | Danish Krona |
| | | | 0.8663137 | GBP | Pound Sterling |
| | | | 155.7912512 | JPY | Japanese Yen |
| | | | 11.2168157 | NOK | Norwegian Krona |
| | | | 11.1283413 | SEK | Swedish Krona |
| | | | 1.1045500 | USD | US Dollar |

Rhenman & Partners Fund

Notes to the financial statements (continued)

as at 31st December 2023

h) Short sales

When a Sub-Fund engages in a short sale, an amount equal to the proceeds received by the Sub-Fund is reflected as an asset and equivalent liability. The amount of the liability is subsequently marked to market to reflect the market value of the short sale. The Sub-Fund is exposed to the risk of depreciation to the extent that the market value of the security sold short exceeds the proceeds of the short sales.

Securities sold short are borrowed from the prime broker.

i) Transaction fees

Transaction costs disclosed under the item "Transaction fees" in the expenses of the statement of operations are mainly composed of broker fees incurred by the Fund and of fees relating to transactions paid to the Depositary and of fees relating to transactions paid to the depositary as well as of transaction fees on financial instruments and derivatives.

Note 3 - Central administration costs

Central administration fees are disclosed in the item "Central administration costs" in the statement of operations.

Note 4 - Depositary fees

The Depositary fees are disclosed in the item "Depositary fees" in the statement of operations. This item includes also the Supervisor fees.

Note 5 - Dilution Levy

Under certain circumstances (for example, large volumes of deals) investment and/or disinvestment costs may have an adverse effect on the unitholder's interest in the Sub-Fund. In order to prevent this effect, called "dilution", the Management Company has the power to charge a "dilution levy" on the issue, redemption and/or conversion of units of the Sub-Fund. If charged, the dilution levy will be paid into the Sub-Fund.

The dilution levy will be calculated by reference to the costs of dealing in the underlying investments of the Sub-Fund, including any dealing spreads, commission and transfer taxes.

The need to charge a dilution levy will depend on the volume of issues, redemptions or conversions. The Management Company may charge a discretionary dilution levy on the issues, redemptions and conversions of units, if in its opinion, the existing Unitholders (for issues) or remaining Unitholders (for redemptions) might otherwise be adversely affected.

In any case, the dilution levy shall not exceed 2% of the Net Asset Value per Unit.

Note 6 - Management fees

The AIFM is entitled to receive out of the Sub-Fund's assets a management fee of 0.075% p.a., consisting of an infrastructure fee (0.025% p.a. with a maximum of EUR 75.000 p.a.) and the AIFM fee (0.05% p.a.).

The Portfolio Manager receives out of the Sub-Fund's assets an annual portfolio management services fees, calculated for each Valuation Day, consisting of (a) the investment management fee paid out monthly of:

- 2.00% p.a. for the classes RC1 (EUR), RC1 (SEK),
- 1.50% p.a. for the classes RC2 (SEK), IC1 (EUR), IC1 (USD), ID1 (SEK),
- 0.75% p.a. for the classes IC3 (EUR),
- 1.00% p.a. for the classes IC2 (SEK), IC2 (USD) and RC2 (USD),

Rhenman & Partners Fund

Notes to the financial statements (continued)

as at 31st December 2023

- 0.75% p.a. for the classes IC4 (EUR).

and of (b) the research fee of maximum 0.30% p.a. paid out quarterly in arrears.

Note 7 - Performance fees

The Portfolio Manager is also entitled to receive a performance fee, payable out of the Sub-Fund's assets.

Calculation of the performance fee for all classes except for Class IC4 (EUR)

The performance fee is calculated and accrued monthly in the respective unit classes as described below and is paid out quarterly in arrears. The first period ended on 30th June 2009 and being followed by each successive quarter thereafter (the "Calculation Period").

For each Calculation Period, the performance fee in respect of each unit is equal to 20% of the appreciation in the Gross Asset Value per each Unit of that class during the Calculation Period above the Base Net Asset Value per each Unit of that class. For Class D Units the Gross Net Asset Value (GNAV) used for the calculation of the Performance Fee will be adjusted by any dividend distributions made during the relevant Calculation Period.

The Gross Net Asset Value is calculated after the accrual of all fees but prior to the accrual of any Performance Fee on the relevant Valuation Day.

The Base Net Asset Value per each Unit is the greater of the Net Asset Value of that Unit at the time of issue of that Unit Class multiplied by the 3 months EURO Interbank Offered Rate on the last business day of the previous calculation period adjusted for monthly return and the highest Gross Net Asset Value of that Unit achieved as of the end of any previous Calculation Period (if any) during which such Unit was in issue multiplied by the 3 months EURO Interbank Offered Rate for the relevant calculation period adjusted for monthly return. The calculation cannot be based on a negative EURO Interbank Offered Rate.

For the Class IC2 Units, certain adjustments will be made to reduce inequities that would occur for investors subscribing for Units at a time when the Net Asset Value per Unit is other than the Peak Net Asset Value per Unit (Equalisation).

For Class IC4 (EUR)

For Class IC4 (EUR) Units, the performance fee is calculated and accrued monthly and is paid out annually in arrears. The Calculation Period will start on 1st January and end on 31st December each year. For each Calculation Period, the performance fee in respect of each unit is equal to 10%.

The Portfolio Manager shall be entitled to a Performance Fee if the Sub-Fund produces an excess performance, defined as any positive difference between the performance of the current Gross Net Asset Value (GNAV) per Unit and the Base Net Asset Value per Unit for the same calculation period. If the difference is negative, excess performance is defined to be zero, and in such case the Portfolio Manager is not entitled to a Performance Fee and the negative performance at the end of any Calculation Period will not be carried forward to the next Calculation Periods. A Performance Fee will only be paid if the excess performance is above a 5% annual hurdle rate and if that is the case the Performance Fee will be calculated on the entire difference between the GNAV and the Base Net Asset Value.

The GNAV is calculated after the accrual of all fees but prior to the accrual of any Performance Fee on the relevant Valuation Day.

The Base Net Asset Value per each Unit is equal to the Net Asset Value of that Unit at the end of the previous Calculation Period.

In the case of Units redeemed during a Calculation Period, the accrued Performance Fee in respect of those Units shall be crystallized and subsequently paid to the Portfolio Manager at the end of the Calculation Period.

Rhenman & Partners Fund

Notes to the financial statements (continued)
as at 31st December 2023

| Sub-Fund | Unit class | Performance fee amount in Sub-Fund currency | Performance fee ratio in % of average total net assets |
|--|------------|--|---|
| Rhenman & Partners Fund - Rhenman Healthcare Equity L/S | IC2 (SEK) | 133,343.18 | 1.13% |
| | IC4 (EUR) | 1,403,742.23 | 0.83% |
| | ID1 (SEK) | 662,697.90 | 1.24% |
| | RC1 (SEK) | 2,217,732.80 | 1.22% |
| | RC2 (SEK) | 2,904,924.90 | 1.35% |
| | | 7,322,441.01 | |
| | | EUR | |

Note 8 - Subscription duty ("taxe d'abonnement")

The Fund is governed by Luxembourg law.

Pursuant to the legislation and regulations in force, the Fund is subject to an annual subscription duty ("*taxe d'abonnement*") of 0.05% which is payable quarterly and calculated on the basis of the net assets of each Sub-Fund on the last day of each quarter.

Pursuant to Article 175 (a) of the amended law of 17th December 2010 the net assets invested in Undertakings for Collective Investment already subject to the "*taxe d'abonnement*" are exempt from this tax.

The rate of this tax may be reduced to 0.01% of the value of the net assets for Sub-Fund or classes of units reserved to institutional investors (Class I units).

Note 9 - Pledged assets

At the date of the financial statements, the following securities serve as pledged assets in relation to collateralized debt at banks, short sales and security borrowing operations. The counterparty of the following positions is Skandinaviska Enskilda Banken AB (publ), Stockholm.

| Description | Currency | Quantity | Market value (in EUR) |
|-----------------------------|----------|------------|--------------------------|
| Abbott Laboratories | EUR | 205,000.00 | 20,428,545.56 |
| AbbVie Inc | EUR | 167,000.00 | 23,430,347.20 |
| Alkermes Plc | EUR | 300,000.00 | 7,534,289.98 |
| Anylam Pharmaceuticals Inc | EUR | 37,500.00 | 6,498,460.91 |
| AstraZeneca Plc | EUR | 302,000.00 | 36,731,170.48 |
| Biogen Inc | EUR | 56,500.00 | 13,236,616.72 |
| BioMarin Pharmaceutical Inc | EUR | 282,500.00 | 24,660,404.69 |
| Boston Scientific Corp | EUR | 750,000.00 | 39,253,542.17 |
| Cencora Inc | EUR | 96,000.00 | 17,850,237.65 |
| Cigna Group Reg | EUR | 9,000.00 | 2,439,952.92 |
| CVS Health Corp | EUR | 137,500.00 | 9,829,342.27 |
| Danaher Corp | EUR | 50,000.00 | 10,472,137.97 |
| Dexcom Inc | EUR | 100,000.00 | 11,234,439.36 |
| Elevance Health Inc | EUR | 13,000.00 | 5,550,024.90 |
| Eli Lilly & Co | EUR | 78,005.00 | 41,166,696.48 |
| Exact Sciences Corp Reg | EUR | 165,000.00 | 11,051,287.85 |
| Genmab A/S | EUR | 30,000.00 | 8,672,745.27 |
| Gilead Sciences Inc | EUR | 210,000.00 | 15,401,837.85 |
| HCA Healthcare Inc | EUR | 50,000.00 | 12,252,953.69 |

Rhenman & Partners Fund

Notes to the financial statements (continued)
as at 31st December 2023

| Description | Currency | Quantity | Market value (in EUR) |
|-------------------------------|----------|------------|--------------------------|
| Humana Inc | EUR | 17,000.00 | 7,046,100.22 |
| Jazz Pharmaceuticals Plc | EUR | 123,634.00 | 13,767,581.37 |
| Medtronic Plc Reg | EUR | 535,000.00 | 39,901,588.88 |
| Merck & Co Inc | EUR | 147,500.00 | 14,558,372.19 |
| Neurocrine Biosciences Inc | EUR | 34,566.00 | 4,123,322.76 |
| Privia Health Group Inc | EUR | 200,000.00 | 4,170,023.99 |
| Regeneron Pharmaceuticals Inc | EUR | 30,000.00 | 23,854,691.96 |
| ShockWave Medical Inc Reg | EUR | 50,000.00 | 8,626,137.34 |
| Tenet Healthcare Corp Reg | EUR | 200,000.00 | 13,683,400.48 |
| Thermo Fisher Scientific Inc | EUR | 500.00 | 240,274.32 |
| United Health Group Inc | EUR | 35,000.00 | 16,682,314.06 |
| Vertex Pharmaceuticals Inc | EUR | 95,000.00 | 34,995,744.87 |
| Xencor Inc | EUR | 150,000.00 | 2,883,074.56 |
| | | | <u>502,227,660.92</u> |

Note 10 - Collateralized debt at banks

Collateralized debt at banks is money borrowed from Skandinaviska Enskilda Banken AB (publ), Stockholm to leverage the portfolio.

| Sub-Fund | Currency | Collateralized debt | Interest payable on collateralized debt | Collateralized debt including interest |
|---|----------|---------------------|---|--|
| Rhenman & Partners Fund - Rhenman Healthcare Equity L/S | EUR | 190,677,123.07 | 32,254.85 | 190,709,377.92 |

Note 11 - Securities lending

The Fund can carry out securities lending transactions.

As at 31st December 2023, the following securities lending is committed with Skandinaviska Enskilda Banken AB (publ), Stockholm:

| Sub-Fund | Currency | Global Exposure |
|---|----------|-----------------|
| Rhenman & Partners Fund - Rhenman Healthcare Equity L/S | USD | 1,221,710.20 |

Note 12 - Changes in the investment portfolio

The statement of changes in the investment portfolio for the period covered by the report is available free of charge upon request from the registered office of the AIFM.

Note 13 - Sustainability-related disclosures

In accordance with the requirements of the Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector (the "SFDR") as amended and as complemented by regulatory technical standards (RTS), it is noted that the Sub-Fund is categorised under SFDR Article 6.

The investments underlying the Sub-Fund do not take into account the EU criteria for environmentally sustainable economic activities.

Rhenman & Partners Fund

Notes to the financial statements (continued)

as at 31st December 2023

Note 14 - Events

Xavier Parain resigned from the Board of Directors of FundRock Management Company S.A. on 10th February 2023 and David Rhydderch was appointed by co-optation to the Board on 5th May 2023.

Romain Denis resigned from the Board of Directors of FundRock Management Company S.A. on 17th July 2023 and Karl Führer was appointed as a director in his place.

Frank de Boer was appointed to the Board of Directors of FundRock Management Company S.A. on 7th August 2023.

The Board of Directors of the Management Company (the Board) informed by notice to the shareholders dated 25th September 2023 about the change of the Global Distributor of the Fund from FundRock Management Company S.A. to FundRock Distributions S.A.. The Board also decided to reintroduce securities lending services. These changes became effective as of 25th October 2023.

Note 15 - Subsequent events

The Board of Directors of the Management Company approved on 20 November 2023 to lower the management fee from 1% p.a. to 0.75% p.a. in Class RC2 USD, ISIN LU0417597985, for the Sub-Fund Rhenman and Partners Fund - Rhenman Healthcare Equity L/S. The change becomes effective as of 1st January 2024.

Rhenman & Partners Fund

Additional information (unaudited)
as at 31st December 2023

1 - Risk management disclosure

1.1. Risk Profile

The current risk profile of the Sub-Fund has been reviewed during the reporting period without material changes. The AIFM/Management Company monitors the overall risk profile of the Fund, including market, liquidity, counterparty as well as the level of the leverage.

No limits as set by the Board of Directors of the AIFM/Management Company as part of the risk profile have been exceeded or are likely to be exceeded by the Sub-Fund.

1.2. Risk Management systems

The risk monitoring is based on the risk management process adopted by the Board of Directors of the AIFM/Management Company and is performed independently from the portfolio management. No changes have been applied to the risk management procedures.

1.3. Leverage

In accordance with the Law of 12th July 2013 (the "2013 Law"), the maximum level of leverage which the AIFM is entitled to employ on behalf of Rhenman & Partners Fund is 300% in accordance with the commitment method and 400% in accordance with the gross method of the total assets.

The AIFM calculates the leverage on a gross and on a commitment method in accordance with Article 7 and Article 8 of the Commission Delegated Regulation EU/231/2013 (the "AIFM Regulation") on a monthly basis. The gross method converts all positions on derivative financial instruments into equivalent positions in the underlying assets, while the commitment method applies the same while allowing netting and hedging arrangements.

The level of leverage during the reporting period is disclosed below:

| Sub-Fund | Internal Leverage -limit | Gross Method Leverage | | | |
|---|------------------------------|----------------------------|---------|---------|--------------------------|
| | | Minimum | Average | Maximum | As at 31st December 2023 |
| Rhenman & Partners Fund - Rhenman Healthcare Equity L/S | 400% Gross (300% Commitment) | 125.56% | 135.12% | 144.90% | 129.62% |
| | | Commitment Method Leverage | | | |
| | | Minimum | Average | Maximum | As at 31st December 2023 |
| | | 120.91% | 132.90% | 143.08% | 129.18% |

2 - Remuneration disclosure

2.1. Remuneration of the Management Company

FundRock Management Company S.A. ("FundRock") as subject to CSSF Circular 18/698 has implemented a remuneration policy in compliance with Articles 111a and 111b of the 2010 Law and/or Article 12 of the 2013 Law respectively.

FundRock as subject to Chapter 15 of the 2010 Law and AIFM must also comply with the guidelines of the European Securities and Markets Authority ESMA/2016/5758 and ESMA/2016/5799 to have sound processes in place. FundRock has established and applies a remuneration policy in accordance with the ESMA Guidelines on sound remuneration policies under the UCITS V Directive (ESMA 2016/575) and AIFMD (ESMA 2016/579) and any related legal & regulatory provisions applicable in Luxembourg.

Rhenman & Partners Fund

Additional information (unaudited) (continued)

as at 31st December 2023

Further, consideration has been given to the requirements as outlined in Regulation (EU) 2019/2088 on sustainability - related disclosures in the financial sector, the SFDR Requirements.

The remuneration policy is aligned with the business strategy, objectives, values and interests of FundRock and the Funds that it manages and of the investors in such Funds, and which includes, inter alia, measures to avoid conflicts of interest; and it is consistent with and promotes sound and effective risk management and does not encourage risk taking which is inconsistent with the risk profiles, rules or instruments of incorporation of the Funds that the Management Company manages.

FundRock ensures that its remuneration policy adequately reflects the predominance of its oversight activity within its core activities. As such, it should be noted that FundRock's employees who are identified as risk-takers are not remunerated based on the performance of the funds under management.

A paper version of the remuneration policy is made available free of charge to investors at FundRock's registered office. FundRock's remuneration policy can also be found at:
<https://www.fundrock.com/policies-and-compliance/remuneration-policy/>

The total amount of remuneration for the financial year ending 31 December 2023 paid by FundRock to its staff:
EUR 14,194,779
Fixed remuneration: EUR 13,452,850
Variable remuneration: EUR 741,929
Number of beneficiaries: 208

The aggregated amount of remuneration for the financial year ending 31 December 2023 paid by FundRock to Identified staff/risk takers is EUR 1,867,063.

The total amount of remuneration is based on a combination of the assessment of the performance of the individual, the overall results of FundRock, and when assessing individual performance, financial as well as non-financial criteria are taken into account.

The Policy is subject to annual review by the Compliance Officer and the update is performed by HR department of FundRock and is presented for review to the Remuneration Committee and approval by the Board of FundRock.

2.2 Remuneration of the Investment Manager

The remuneration to Rhenman & Partners Asset Management AB for the period from 1st September 2022 till 31st August 2023:

Number of employees: 10
Total compensation to staff: SEK 40,535,575
Of which compensation to management: SEK 11,234,117

The Portfolio Manager receives out of the Sub-Fund's assets an annual portfolio management services fees, calculated for each Valuation Day, consisting of the research fee of maximum 0.30% p.a. paid out quarterly in arrears.

Rhenman & Partners Fund

Additional information (unaudited) (continued)
as at 31st December 2023

3 - Information concerning the transparency of securities financing transactions and of reuse of cash collateral (regulation EU 2015/2365, hereafter "SFTR")

At the date of the financial statements, the Fund is concerned by securities borrowing operations and securities lending operations for the following portfolios in the context of the requirements of the SFTR regulation 2015/2365 on transparency of securities financing transactions and of reuse of collateral.

| | Rhenman & Partners Fund- Rhenman Healthcare Equity L/S (in EUR) |
|--|--|
| Global data: assets used for securities borrowing | |
| in absolute terms | 111,396,706.05 |
| as a percentage of lendable assets of the Sub-Fund | 9.64% |
| Global data: assets used for securities lending | |
| in absolute terms | 1,221,710.20 |
| as a percentage of lendable assets of the Sub-Fund | 0.11% |
| Concentration data | |
| 10 largest collateral issuers | |
| first | - |
| gross volumes for open trades | - |
| Top 10 counterparties of securities borrowing | |
| name of counterparty | Skandinaviska Enskilda Banken AB (publ) |
| gross volume of outstanding transactions | 111,396,706.05 |
| Top 10 counterparties of securities lending | |
| name of counterparty | Skandinaviska Enskilda Banken AB (publ) |
| gross volume of outstanding transactions | 1,221,710.20 |
| Aggregate transaction data | |
| Country (countries) in which the counterparties are established | SE |
| Type of settlement and clearing for securities borrowing | |
| tri-party | - |
| Central Counterparty | - |
| bilateral | 111,396,706.05 |
| Type of settlement and clearing for securities lending | |
| tri-party | - |
| Central Counterparty | - |
| bilateral | 1,221,710.20 |
| Data on reuse of collateral received | |
| % foreseen in prospectus | no reuse and no pledge |
| collateral received that is reused | - |
| cash collateral reinvestment returns to the Sub-Fund | - |
| Safekeeping of collateral received | |
| number of depositaries | - |
| name of depositaries | - |
| amounts of assets received as collateral | - |
| Safekeeping of collateral granted | |
| segregated accounts | 502,227,660.92 |
| pooled accounts | - |
| other accounts | - |

Rhenman & Partners Fund

Additional information (unaudited) (continued)
as at 31st December 2023

| | Rhenman & Partners Fund- Rhenman Healthcare Equity L/S (in EUR) |
|--|--|
| Return and cost components for securities borrowing | |
| Return component of the Sub-Fund | |
| In absolute terms | - |
| As a percentage of overall returns | 0.00% |
| Cost component of the Sub-Fund | 2 167 425.72 |
| Return component of the capital management company | |
| In absolute terms | - |
| As a percentage of overall returns | 0.00% |
| Cost component of the capital management company | - |
| Return component of third parties | |
| In absolute terms | - |
| As a percentage of overall returns | 0.00% |
| Cost component of third parties | - |
| Return and cost components for securities lending | |
| Return component of the Sub-Fund | |
| In absolute terms | - |
| As a percentage of overall returns | 0.00% |
| Cost component of the Sub-Fund | - |
| Return component of the capital management company | |
| In absolute terms | - |
| As a percentage of overall returns | 0.00% |
| Cost component of the capital management company | - |
| Return component of third parties | |
| In absolute terms | - |
| As a percentage of overall returns | 0.00% |
| Cost component of third parties | - |

There is no fixed maturity date on securities borrowing contracts and securities lending contracts

